Synapse - Elsevier Science, Inc.

Elsevier Science, Inc.

SHERPA: Unknown

People

Scher
Motzer
Bajorin
Morris
Reuter
Rosenberg
Sheinfeld
Feldman
Russo
Solit

Groups

Department of Medicine (389)
Genitourinary Oncology Service (389)
Solid Tumor Oncology Division (389)
Surgery (113)
Urology (109)
Department of Pathology and Laboratory Medicine (65)
Survivorship Research (59)
GSK Faculty (58)
Epidemiology and Biostatistics (51)
Human Oncology and Pathogenesis Program (41)

Search Within

Results (389)

Export to EndNote / Excel

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial

Journal Article

Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Review

Motzer, R. J.; Rane, P. P.; Saretsky, T. L.; Pawar, D.; Martin Nguyen, A.; Sundaram, M.; Burgents, J.; Pandey, R.; Rudell, K.
European Urology (2023)

Fulltext@MSK | Save

Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study

Journal Article

Abida, W.; Campbell, D.; Patnaik, A.; Bryce, A. H.; Shapiro, J.; Bambury, R. M.; Zhang, J.; Burke, J. M.; Castellano, D.; Font, A.; more...
European Urology (2023)

Fulltext@MSK | Save

PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues

Editorial

Beije, N.; Abida, W.; Antonarakis, E. S.; Castro, E.; de Wit, R.; Fizazi, K.; Gillessen, S.; Hussain, M.; Mateo, J.; Morris, M. J.; more...
European Urology (2023)

Fulltext@MSK | Save

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial

Journal Article

Albiges, L.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Stus, V.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study

Journal Article

Pant, S.; Schuler, M.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Minchom, A.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer

Editorial

Abida, W.; Attard, G.
Lancet (2023)

Fulltext@MSK | Save

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial